A Phase 3 interventional study of Cyclosporine Vehicle and Cyclosporine 0.010% in Atopic Conjunctivitis, sponsored by Allergan. Completed at 12 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2012-11-05.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 20th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2009, is one of 34 in phase 3, and was the 22nd registered.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.
Browse Conjunctivitis, Allergic studies →6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 8+
Dompé Farmaceutici S.p.A · Sites in United States, Argentina, Czechia and 11 more countries
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 29 · Phase 3 36 · Phase 4 20
First in 2000; this study’s year is marked. 8 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 176 is above the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 94 across the 90 interventional studies, 100 across the 5 observational. Of the 84 that completed or were terminated, 50 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 95 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 9 studies filed under Conjunctivitis, Allergic — fewer than ten, so there is no comparison to draw.
1 of the studies in Conjunctivitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07938632Telios Pharma, Inc.TL-925 for the Treatment of Allergic Conjunctivitis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the efficacy and safety of Cyclosporine 0.010% eye drops in the treatment of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye). The study consists of a double-masked phase, and open-labeled phase, and an open-labeled maintenance phase. For the first 3 months of the study, patients will receive either masked Cyclosporine 0.010% eye drops or vehicle four times daily; for the next 6 months, patients may receive open-labeled Cyclosporine 0.010% eye drops four times daily. At month 9, patients who are in remission, will be re-randomized to receive either open-labeled Cyclosporine 0.010% eye drops four times daily or twice daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
Drug: Cyclosporine 0.010%
Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months followed by cyclosporine ophthalmic solution 0.010% up to 9 additional months; at Month 9 the dose may be adjusted to 2 times a day.
Drug: Cyclosporine Vehicle · Drug: Cyclosporine 0.010%
Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.
Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
Percentage of Treatment Responders
Treatment responders are defined as patients with a ≥ 1 grade improvement from baseline in punctate corneal staining score and a ≥ 4 grade improvement from baseline in composite symptom score in the study eye. The punctate corneal staining score is assessed on a scale of 0 to 5 (0 is ≤2 dots and 5 is \>316 dots (approximately) or ulcer/erosion). The composite symptom score is based on 5 symptoms (itching, tearing, ocular discomfort, photophobia, mucous discharge). The composite symptom score (0 to 15) is the sum of 5 symptoms (each symptom is assessed on a scale of 0=absent to 3=severe).
Time frame: Baseline, Month 2
Percentage of Punctate Corneal Staining Responders
Punctate corneal staining responders defined as patients achieving a punctate corneal staining score of 0 or 1 in the study eye. Punctate corneal staining is assessed on a scale of 0 to 5 where 0 is ≤2 dots, 1 is \>2 dots but ≤ 10 dots, 2 is \> 10 dots but ≤ 32 dots, 3 is \> 32 dots but ≤ 100 dots (approximately), 4 is \> 100 dots (approximately) but ≤ 316 dots (approximately), and 5 is \>316 dots (approximately) or ulcer/erosion.
Time frame: Month 2
Percentage of Patients With an Improvement in the Composite Symptom Score
Composite symptom score improvement is defined as a 4 or more grade decrease from baseline in composite symptom score in the study eye. The composite symptom score is based on 5 symptoms (itching, tearing, ocular discomfort, photophobia, mucous discharge). Each of the 5 symptoms is assessed on a scale of 0=absent to 3=severe. The composite symptom score is the sum of all 5 individual symptom scores, where 0 is no symptoms and 15 is the most severe symptoms.
Time frame: Baseline, Month 2
Percentage of Patients With an Improvement in the Punctate Corneal Staining Score
Punctate corneal staining improvement is defined as a 1 or more grade decrease from baseline in the study eye. The punctate corneal staining score is assessed on a scale of 0 to 5 where 0 is ≤2 dots, 1 is \>2 dots but ≤ 10 dots, 2 is \> 10 dots but ≤ 32 dots, 3 is \> 32 dots but ≤ 100 dots (approximately), 4 is \> 100 dots (approximately) but ≤ 316 dots (approximately), and 5 is \>316 dots (approximately) or ulcer/erosion.
Time frame: Baseline, Month 2
| Milestone | Cyclosporine Ophthalmic Solution (COS) Followed by COS | Placebo Followed by COS |
|---|---|---|
| Started | 89 | 87 |
| Completed | 79 | 83 |
| Not completed | 10 | 4 |
| Milestone | Cyclosporine Ophthalmic Solution (COS) Followed by COS | Placebo Followed by COS |
|---|---|---|
| Started | 162 | 0 |
| Completed | 147 | 0 |
| Not completed | 15 | 0 |
| Milestone | Cyclosporine Ophthalmic Solution (COS) Followed by COS | Placebo Followed by COS |
|---|---|---|
| Started | 147 | 0 |
| Completed | 144 | 0 |
| Not completed | 3 | 0 |
Treatment responders are defined as patients with a ≥ 1 grade improvement from baseline in punctate corneal staining score and a ≥ 4 grade improvement from baseline in composite symptom score in the study eye. The punctate corneal staining score is assessed on a scale of 0 to 5 (0 is ≤2 dots and 5 is \>316 dots (approximately) or ulcer/erosion). The composite symptom score is based on 5 symptoms (itching, tearing, ocular discomfort, photophobia, mucous discharge). The composite symptom score (0 to 15) is the sum of 5 symptoms (each symptom is assessed on a scale of 0=absent to 3=severe).
| Percentage of Patients | Cyclosporine Ophthalmic Solution (COS) Followed by COS | Placebo |
|---|---|---|
| Percentage of Treatment Responders | 21.3 | 17.2 |
Punctate corneal staining responders defined as patients achieving a punctate corneal staining score of 0 or 1 in the study eye. Punctate corneal staining is assessed on a scale of 0 to 5 where 0 is ≤2 dots, 1 is \>2 dots but ≤ 10 dots, 2 is \> 10 dots but ≤ 32 dots, 3 is \> 32 dots but ≤ 100 dots (approximately), 4 is \> 100 dots (approximately) but ≤ 316 dots (approximately), and 5 is \>316 dots (approximately) or ulcer/erosion.
| Percentage of Patients | Cyclosporine Ophthalmic Solution (COS) Followed by COS | Placebo |
|---|---|---|
| Percentage of Punctate Corneal Staining Responders | 24.7 | 23.0 |
Composite symptom score improvement is defined as a 4 or more grade decrease from baseline in composite symptom score in the study eye. The composite symptom score is based on 5 symptoms (itching, tearing, ocular discomfort, photophobia, mucous discharge). Each of the 5 symptoms is assessed on a scale of 0=absent to 3=severe. The composite symptom score is the sum of all 5 individual symptom scores, where 0 is no symptoms and 15 is the most severe symptoms.
| Percentage of Patients | Cyclosporine Ophthalmic Solution (COS) Followed by COS | Placebo |
|---|---|---|
| Percentage of Patients With an Improvement in the Composite Symptom Score | 30.3 | 28.7 |
Punctate corneal staining improvement is defined as a 1 or more grade decrease from baseline in the study eye. The punctate corneal staining score is assessed on a scale of 0 to 5 where 0 is ≤2 dots, 1 is \>2 dots but ≤ 10 dots, 2 is \> 10 dots but ≤ 32 dots, 3 is \> 32 dots but ≤ 100 dots (approximately), 4 is \> 100 dots (approximately) but ≤ 316 dots (approximately), and 5 is \>316 dots (approximately) or ulcer/erosion.
| Percentage of Patients | Cyclosporine Ophthalmic Solution (COS) Followed by COS | Placebo |
|---|---|---|
| Percentage of Patients With an Improvement in the Punctate Corneal Staining Score | 42.7 | 42.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cyclosporine Ophthalmic Solution (COS) Followed by COS | — | 11/171 (6.4%) | 44/171 (25.7%) |
| Placebo | — | 3/87 (3.4%) | 16/87 (18.4%) |
| Event | Cyclosporine Ophthalmic Solution (COS) Followed by COS | Placebo |
|---|---|---|
| Anaphylactic ShockImmune system disorders | 0/171 | 1/87 |
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/171 | 1/87 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/171 | 1/87 |
| Forearm FractureInjury, poisoning and procedural complications | 1/171 | 0/87 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/171 | 0/87 |
| PneumoniaInfections and infestations | 1/171 | 0/87 |
| Infectious MononucleosisInfections and infestations | 1/171 | 0/87 |
| Prostatic Specific Antigen IncreasedInvestigations | 1/171 | 0/87 |
| Dermatitis AtopicSkin and subcutaneous tissue disorders | 1/171 | 0/87 |
| Abdominal HerniaGastrointestinal disorders | 1/171 | 0/87 |
| Event | Cyclosporine Ophthalmic Solution (COS) Followed by COS | Placebo |
|---|---|---|
| Allergic KeratitisEye disorders | 24/171 | 10/87 |
| BlepharitisEye disorders | 10/171 | 3/87 |
| Punctate KeratitisEye disorders | 10/171 | 3/87 |
| Age, Customized(Participants) | Cyclosporine Ophthalmic Solution (COS) Followed by COS | Placebo Followed by COS | Total |
|---|---|---|---|
| <18 years | 7 | 8 | 15 |
| 18 to <30 years | 15 | 13 | 28 |
| 30 to <50 years | 32 | 38 | 70 |
| 50 to <65 years | 27 | 22 | 49 |
| >=65 years | 8 | 6 | 14 |
| Sex: Female, Male(Participants) | Cyclosporine Ophthalmic Solution (COS) Followed by COS | Placebo Followed by COS | Total |
|---|---|---|---|
| Female | 46 | 39 | 85 |
| Male | 43 | 48 | 91 |
The record gives a start of May 2009, a primary completion of Oct 2010 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 2 years 1 month after primary completion. A results delay was requested in Jan 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclosporine